In recent years, improving downstream manufacturing has become an emerging challenge to the biopharmaceutical industry. Initially, the bottleneck in biopharmaceutical manufacturing existed in the output of bioreactors. Due to advances in cell line development and upstream process (i.e., perfusion), the output of bioreactors has increased at a much faster pace than downstream processing capacity.
November 14 - 16, 2016 | European Antibody Congress, Basel, Switzerland
Visit CMC Biologics at booth #9, during the European Antibody Congress in Basel, Switzerland. Join us at the Congress Center Basel, and learn why CMC Biologics is leading the industry in contract development and manufacturing of monoclonal antibodies and other therapeutic proteins.
CMC Biologics Copenhagen Facility site head Patricio Massera, was honored to participate in the recent Danish State Visit to Korea
CMC Biologics was chosen for inclusion in the state visit, along with representatives from other select Danish companies in the Health Industry, for participation in a Denmark- Korea Roundtable Meeting on Health.